

August 6, 2024



# Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Encinitas, California--(Newsfile Corp. - August 6, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming conferences that will be available to investors by live webcast.

On Tuesday August 13th, 2024 at 3:00 pm Eastern Time, Kiora's President and CEO, Brian Strem, Ph.D., will participate at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase. The presentation will be available live from this [registration link](#) and the replay will be available on-demand for 90 days on our IR homepage ([ir.kiorapharma.com](http://ir.kiorapharma.com)).

On Thursday August 15th, 2024, Kiora's President and CEO, Brian Strem, Ph.D., will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The webcast will be available live from this [registration link](#) and the replay will be available on-demand for 90 days on our IR homepage ([ir.kiorapharma.com](http://ir.kiorapharma.com)).

## About Kiora Pharmaceuticals

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

In addition to news releases and SEC filings, we expect to post information on our website ([www.kiorapharma.com](http://www.kiorapharma.com)) and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.

## Contacts:

Investors  
[investors@kiorapharma.com](mailto:investors@kiorapharma.com)

Media  
[kiora@crowepr.com](mailto:kiora@crowepr.com)  
Crowe PR



To view the source version of this press release, please visit  
<https://www.newsfilecorp.com/release/218902>

SOURCE Kiora Pharmaceuticals, Inc.